EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
-0.09 (-0.49%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.55 - 18.30
52 week 17.34 - 32.85
Open 18.00
Vol / Avg. 1.70M/1.44M
Mkt cap 1.73B
P/E     -
Div/yield     -
EPS -1.61
Shares 96.09M
Beta 1.12
Inst. own 93%
Oct 26, 2015
Q3 2015 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 9, 2015
Exact Sciences Corp at Robert W Baird and Co Health Care Conference
Aug 12, 2015
Exact Sciences Corp at Canaccord Genuity Growth Conference
Aug 11, 2015
Exact Sciences Corp at Wedbush PacGrow Healthcare Conference
Jul 23, 2015
Exact Sciences Corp Annual Shareholders Meeting - Webcast
Jul 20, 2015
Q2 2015 Exact Sciences Corp Earnings Call
Jul 20, 2015
Q2 2015 Exact Sciences Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -481.17% -5564.40%
Operating margin -484.86% -5591.71%
EBITD margin - -5385.37%
Return on average assets -58.93% -43.55%
Return on average equity -64.88% -47.16%
Employees 236 -
CDP Score - -


441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non‑invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non‑invasive stool‑based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody‑based fecal immunochemical test (FIT). The Company's Cologuard test is designed to detect pre‑cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre‑cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The company's test also detects blood in stool, utilizing an antibody based FIT test.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 53
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 64
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 60
Bio & Compensation  - Reuters